Drug Profile
SVX 1
Alternative Names: SVX-1Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Vaxeal Holding
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder cancer; Pancreatic cancer; Prostate cancer; Renal cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Bladder-cancer in Switzerland (Parenteral)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Pancreatic-cancer in Switzerland (Parenteral)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Prostate-cancer in Switzerland (Parenteral)